Coya Therapeutics (COYA) announced that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia, or FTD. The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital. Topline results of the study will be leveraged to inform and finalize the planned trial design of a company-sponsored, randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD. Coya has been awarded $5M by the Alzheimer’s Drug Discovery Foundation, or ADDF, to support the development of COYA 302 in FTD.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COYA:
- Coya Therapeutics initiated with a Buy at D. Boral Capital
- Coya Therapeutics files to sell 1.38M shares of common stock for holders
- Coya: COYA 301 – GLP-1 agonists combo synergistic in inflamation amelioration
- Coya Therapeutics Reports Q3 2024 Highlights and Progress
- Coya Therapeutics Advances Pipeline for Neurodegenerative Diseases
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
